UBS Group’s Anebulo Pharmaceuticals ANEB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,334
| Closed | -$2.36K | – | 10442 |
|
|
2025
Q4 | $2.36K | Buy |
2,334
+2,114
| +961% | +$4.82K | ﹤0.01% | 9325 |
|
|
2025
Q3 | $550 | Buy |
220
+128
| +139% | +$301 | ﹤0.01% | 9630 |
|
|
2025
Q2 | $132 | Buy |
92
+91
| +9,100% | +$104 | ﹤0.01% | 9974 |
|
|
2025
Q1 | $1 | Sell |
1
-24
| -96% | -$35 | ﹤0.01% | 10157 |
|
|
2024
Q4 | $42 | Sell |
25
-738
| -97% | -$1.22K | ﹤0.01% | 9721 |
|
|
2024
Q3 | $1.47K | Buy |
+763
| New | +$1.63K | ﹤0.01% | 8630 |
|
|
2024
Q2 | – | Sell |
-144
| Closed | -$413 | – | 9484 |
|
|
2024
Q1 | $413 | Buy |
+144
| New | +$371 | ﹤0.01% | 8575 |
|
|
2023
Q1 | – | Sell |
-1,696
| Closed | -$4.1K | – | 9559 |
|
|
2022
Q4 | $4.1K | Sell |
1,696
-1,085
| -39% | -$2.86K | ﹤0.01% | 9385 |
|
|
2022
Q3 | $8K | Sell |
2,781
-128
| -4% | -$455 | ﹤0.01% | 8686 |
|
|
2022
Q2 | $15K | Buy |
2,909
+753
| +35% | +$3.15K | ﹤0.01% | 7274 |
|
|
2022
Q1 | $15K | Buy |
2,156
+1,576
| +272% | +$10.8K | ﹤0.01% | 7814 |
|
|
2021
Q4 | $4K | Sell |
580
-268
| -32% | -$1.78K | ﹤0.01% | 9494 |
|
|
2021
Q3 | $6K | Buy |
848
+614
| +262% | +$4.3K | ﹤0.01% | 8404 |
|
|
2021
Q2 | $2K | Buy |
+234
| New | +$1.74K | ﹤0.01% | 8924 |
|
UBS Group's ANEB Position: Q1 2026 in Review
UBS Group sold out of Anebulo Pharmaceuticals (ANEB) in Q1 2026, closing a stake of 2,334 shares — an estimated $2.36K sold.
UBS Group first reported a position in ANEB in Q2 2021 and held it in 14 quarters. The position peaked at $15K in Q2 2022. 0 funds tracked by Wall St. Rank hold ANEB as of Q1 2026.
- UBS Group reported no remaining Anebulo Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- UBS Group sold 2,334 Anebulo Pharmaceuticals shares in Q1 2026, an estimated $2.36K.
- UBS Group first reported a position in Anebulo Pharmaceuticals in Q2 2021 and held it in 14 quarters.
- UBS Group's Anebulo Pharmaceuticals position peaked at $15K in Q2 2022.
- 0 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.